Related Experiment Video
Updated: Dec 12, 2025

Implementation of a Hyperbolic Vortex Plasma Reactor for the Removal of Micropollutants in Water
Published on: July 25, 2025
Exploring reductive degradation of fluorinated pharmaceuticals using Al2O3-supported Pt-group metallic catalysts:
Jaehyeong Park1, Seonyoung An1, Eun Hea Jho2
1Department of Civil and Environmental Engineering and Institute of Construction and Environmental Engineering, Seoul National University, 35-402, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Republic of Korea.
Abstract:
Recently, an increasing number of pharmaceutical compounds has become fluorinated. Owing to their pharmacological efficacy, the use of these fluorinated pharmaceuticals continues to grow, and they constitute 20% of the drugs on the current market. However, only a few studies have investigated the fate and transformation of these emerging contaminants in natural and engineered aquatic environments. In the present study, the H2-based reductive transformation of three fluorinated pharmaceutical compounds (levofloxacin, sitagliptin, and fluoxetine) were investigated using alumina-supported monometallic and bimetallic catalysts of the Pt-group noble metals (i.e., Ru, Rh, Pd, and Pt) under ambient temperature and pressure conditions. Degradation of all three compounds was observed with catalytic reactivity ranging from 4.0 × 10-3 to 2.14 × 102 L/(min·gcat), in which fluoxetine generally showed the highest reactivity, followed by sitagliptin and levofloxacin. The fluorination yields and transformation products were characterized for each fluorinated compound and three different degradation mechanisms were elucidated: 1) hydrodefluorination of C-F bond to CH bond, 2) hydrogenation of aromatic ring, and 3) reductive cleavage of CO bond from phenyl ether. Toxicity assessment using Aliivibrio fischeri showed there were no significant changes in toxicity over levofloxacin and sitagliptin degradation, suggesting the formation of no highly toxic by-products during catalytic reduction. For fluoxetine, an increased toxicity was observed during its degradation while ECOSAR-predicted toxicity values of all identified intermediates were lower than that of fluoxetine, suggesting the formation of unidentified secondary by-products that contribute to the overall toxicity. The study showed that catalytic reduction is a promising remediation process for treating and defluorinating the fluorinated pharmaceutical compounds.
More Related Videos
Related Concept Videos
Phase I Reactions: Reductive Reactions
Radical Substitution: Hydrogenolysis of Alkyl Halides with Tributyltin Hydride
The bonds formed in this reaction are stronger than the bonds broken, making it energetically favorable. The reaction follows a radical chain mechanism similar to radical halogenation reactions,...
Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
Phase I Oxidative Reactions: Overview
Reduction of Alkynes to cis-Alkenes: Catalytic Hydrogenation
Like alkenes, alkynes can be reduced to alkanes in the presence of transition metal catalysts such as Pt, Pd, or Ni. The reaction involves two sequential syn additions of hydrogen via a cis-alkene intermediate.
Reduction of Alkenes: Asymmetric Catalytic Hydrogenation
The metal catalyst used can be either heterogeneous or homogeneous. When hydrogenation of an alkene generates a chiral center, a pair of enantiomeric products is expected to form. However, an enantiomeric excess of one of the products can be facilitated using an enantioselective reaction or an...

